PhD in Immunology, Bio Sorbonne Paris Cité Doctoral School, Paris (France).
European Master in Genetics, University of Paris-Diderot and Milan-Bicocca in joint supervision.
Master in Biotechnologies, University of Milan-Bicocca (Milan), Italy.
Bachelor in Biotechnologies, University of Milan-Bicocca (Milan), Italy
The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells Camilla Panetti, Rahel Daetwyler, Anja Moncsek, Nikolaos Patikas, Andreas Agrafiotis, Adelynn Tang, Francesco Andreata, Valeria Fumagalli, Jean De Lima, Lifen Wen, Carolyn G. King, Ajithkumar Vasanthakumar, Matteo Iannacone, Axel Kallies, Alexander Yermanos, Martin Hemberg, Nicole Joller Nature Immunology, 2025 The co-inhibitory receptor TIGIT suppresses excessive immune responses in autoimmune conditions while also restraining antitumor immunity. In viral infections, TIGIT alone does not affect viral control but has been shown to limit tissue pathology. However, the underlying mechanisms are incompletely understood. Here we found TIGIT+ T cells to express not only an immunoregulatory gene signature but also a tissue repair gene signature. Specifically, after viral infection, TIGIT directly drives expression of the tissue growth factor amphiregulin (Areg), which is strongly reduced in the absence of TIGIT. We identified regulatory T (Treg) cells, but not CD8+ T cells, as the critical T cell subset mediating these tissue-protective effects. In Treg cells, TIGIT engagement after T cell antigen receptor stimulation induces the transcription factor Blimp-1, which then promotes Areg production and tissue repair. Thus, we uncovered a nonclassical function of the co-inhibitory receptor TIGIT, wherein it not only limits immune pathology by suppressing the immune response but also actively fosters tissue regeneration by inducing the tissue growth factor Areg in T cells.
Dendritic cells in focus: mapping functional diversity through technological innovation Francesco Andreata, Francesca Granucci, Laura Marongiu FEBS Letters, 2025 Since their initial identification by Ralph Steinman and Zanvil Cohn in the 1970s [[1]], dendritic cells (DCs) have been established as critical regulators of immune responses. While initially characterized as a relatively homogeneous population of potent antigen-presenting cells responsible for priming naïve T lymphocytes, it is now recognized that DCs comprise a complex and heterogeneous network of subsets. These include conventional DCs (cDC1 and cDC2), plasmacytoid DCs (pDCs), and monocyte-derived inflammatory DCs, each exhibiting distinct developmental origins, surface marker expression, and specialized functional properties. The phenotypic and functional characteristics of DCs are significantly influenced by the tissue microenvironment in which they reside, with DCs in the skin, lung, intestine, lymph nodes, and tumors demonstrating context-specific programs. This remarkable plasticity underscores the role of DCs not only as initiators of immunity but also as dynamic modulators of immune homeostasis, tolerance, and inflammation. The FEBS Letters Special Issue ‘Dendritic cells in health and disease’ focuses on recent conceptual and technological advancements that are refining our understanding of DC biology (Fig. 1). The included articles investigate DCs across diverse tissues and disease states, highlighting the translation of technological innovation into novel therapeutic perspectives. A fundamental aspect of understanding DC identity lies in recognizing that context is a critical determinant of their properties. Whether located within a lymph node or residing in the lung, DCs exhibit adaptability in their morphology, function, and fate. The coordinated action of resident and migratory DCs in lymph nodes, a topic further explored in this issue, illustrates the influence of the spatial and temporal dynamics of immune cell interactions on T-cell activation. Expanding beyond tissue architecture, the liver provides a relevant example of the intricate relationship between metabolic cues and immune regulation, positioning immunometabolism as a central aspect of DC biology. In their Review, Klaimi et al. [[2]] examine hepatic DCs as integrators of dietary, microbial, and metabolic signals. Their work elucidates how these cells modulate their functions to promote either immune tolerance or inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). By integrating data from animal models and human pathology, they emphasize the liver as a key site of convergence between immune and metabolic regulation, with DCs occupying a pivotal position at this interface. To further delineate the evolving understanding of DC heterogeneity, this Special Issue features a series of Reviews providing both mechanistic insights and methodological guidance. In their Review, Protti and Spreafico offer a comprehensive guide to the application of single-cell RNA sequencing (scRNA-seq) in DC research [[3]]. Their article details the technical and computational workflow, demonstrating the utility of scRNA-seq in the high-resolution dissection of DC subsets and their ontogeny. Importantly, they also outline strategies for the integration of transcriptomic data with surface marker analysis and functional assays, providing a framework for the classification and comparison of DC populations across various conditions. Building on the theme of cellular diversity, Nelli and Kuka introduce the concept of TDCs, a novel population co-expressing dendritic and T-cell markers. Their ‘In a Nutshell’ article explores the ontogeny, molecular profile, and potential immunological functions of these cells, challenging conventional lineage definitions and calling for a re-evaluation of immune cell classification [[4]]. The identification of TDCs highlights the importance of high-dimensional analytical tools and flexible conceptual frameworks for the identification of rare or transitional populations within the immune system. The application of spatial biology is increasingly essential for a comprehensive understanding of cellular behavior, incorporating not only molecular identity but also the spatial context of cellular interactions. This approach complements traditional transcriptomic and phenotypic analyses by providing information regarding cellular localization and interaction networks. In the context of DCs, their spatial positioning within tissues, their interactions with neighboring cells, and their migratory patterns are proving to be significant determinants of their function. Reflecting this trend, Rocca et al. [[5]] explore current spatial technologies in their ‘In a Nutshell’ article. Multiplex immunofluorescence and spatial transcriptomics enable the mapping of DCs within their native environments and reveal how tissue structure and cellular neighborhoods influence DC function, particularly in complex environments, such as tumors and mucosal surfaces. From a translational perspective, Morali et al. [[6]] provide an in-depth overview of IL-10-producing tolerogenic DCs (tolDCs) as potential cellular therapies for autoimmunity and transplantation. Their Review discusses the molecular mechanisms underlying tolDC function, the challenges associated with maintaining phenotypic stability, and the current limitations in clinical translation. Complementing these mechanistic and therapeutic perspectives, Dotta et al. [[7]] examine the dynamic regulation of antigen and leukocyte trafficking by DCs within lymph nodes. Their ‘In a Nutshell’ article highlights the interplay between resident and migratory DCs, the role of spatial compartmentalization, and the temporal aspects of activation signals in shaping the efficiency and quality of T-cell priming. Reflecting on the intersection between subset diversity and translational relevance, Barcelos et al. [[8]] examine how DCs are dynamically reprogrammed within the tumor microenvironment and evaluate strategies to restore or harness their function for cancer immunotherapy. Their Review offers a detailed analysis of DC subset ontogeny, highlights the influence of immunosuppressive signals on DC plasticity, and discusses therapeutic avenues, including mRNA vaccines, CD40 agonists, and in situ cellular reprogramming. Emphasizing insights from spatial and single-cell technologies, they propose a framework for designing context-aware, subset-specific interventions to overcome tumor-induced immune dysfunction. The contributions within this Special Issue underscore the multifaceted nature of DC biology. Encompassing single-cell and spatial technologies, the identification of novel cell types, and the development of therapeutic strategies, these articles collectively illustrate a field in the midst of important breakthroughs. The convergence of technological innovation, functional analysis, and clinical insights is redefining our approach to studying and manipulating DCs. Continued interdisciplinary collaboration will be crucial in realizing the full diagnostic and therapeutic potential of DCs. Francesco Andreata is an Assistant Professor of Applied Biology at Vita-Salute San Raffaele University. His research explores how the liver microenvironment shapes CD8 T-cell dysfunction during chronic infections and cancer, with a focus on developing targeted immunotherapies. He has received the MERU Foundation Career Development Award, a Starting Grant from the Italian Science Fund (FIS), and the Antonio Feltrinelli Prize for Biology (under 40) from the Accademia Nazionale dei Lincei. Francesca Granucci is Full Professor of General Pathology at the Department of Biotechnology and Biosciences, University of Milano-Bicocca. She leads a research group focused on innate immunity, with particular emphasis on dendritic cell biology. Her work has significantly advanced the understanding of host–pathogen interactions, elucidating the roles of CD14 and the NFAT signaling pathway in regulating immune responses to bacterial and fungal infections. Her scientific contributions have been recognized with several awards, including the EFIS-EJI Ita Askonas Award in 2012 and the IUBMB Jubilee Medal in 2019. Laura Marongiu is an Assistant Professor of General Pathology at the Department of Biotechnology and Biosciences, University of Milano-Bicocca. Her research is focused on the molecular regulation of immune responses and stem cell biology, with particular emphasis on the CaN-NFAT signaling pathway. Her current studies investigate the therapeutic potential of modulating calcineurin signaling to promote endogenous stem cell expansion and tissue regeneration. She has been awarded competitive research funding from the Italian Multiple Sclerosis Association (AISM) and from the Italian Ministry of University and Research (MIUR) through a PRIN grant, and has received the Young Talents Award from the University of Milano-Bicocca.
Doxorubicin-Loaded Ferritin Nanocages Mitigate Toxicity to T-Lymphocytes in Breast Cancer Therapy Serena Mazzucchelli, Marta Sevieri, Francesca Gorgoglione, Ilaria Tagliolini, Beatrice Bignami, Francesco Andreata, Francesco Mainini, Lorena Signati, Francesca Piccotti, Marta Truffi, Arianna Bonizzi3, Leopoldo Sitia, Carlo Morasso, Barbara Tagliaferri, Fabio Corsi World Congress on Recent Advances in Nanotechnology, 2025 Introduction: Doxorubicin (DOX) is a cornerstone in breast cancer (BC) treatment, despite its well-known side effects, including immunotoxicity.While DOX can enhance the anti-tumor immune response by inducing immunogenic cell death in cancer cells, its non-specific cytotoxicity, particularly towards T-lymphocytes, poses a significant drawback.T-cells are essential for the adaptive immune response against tumors, and their depletion or dysfunction due to DOX toxicity can undermine the effectiveness of both the chemotherapy and the immune system's capacity to combat the cancer.Therefore, developing new formulations of DOX that specifically target tumor cells while sparing immune cells like T-lymphocytes is a critical goal.
Impact of doxorubicin-loaded ferritin nanocages (FerOX) vs. free doxorubicin on T lymphocytes: a translational clinical study on breast cancer patients undergoing neoadjuvant chemotherapy Marta Sevieri, Francesco Andreata, Francesco Mainini, Lorena Signati, Francesca Piccotti, Marta Truffi, Arianna Bonizzi, Leopoldo Sitia, Claudia Pigliacelli, Carlo Morasso, Barbara Tagliaferri, Fabio Corsi, Serena Mazzucchelli Journal of Nanobiotechnology, 2024 Despite the advent of numerous targeted therapies in clinical practice, anthracyclines, including doxorubicin (DOX), continue to play a pivotal role in breast cancer (BC) treatment. DOX directly disrupts DNA replication, demonstrating remarkable efficacy against BC cells. However, its non-specificity toward cancer cells leads to significant side effects, limiting its clinical utility. Interestingly, DOX can also enhance the antitumor immune response by promoting immunogenic cell death in BC cells, thereby facilitating the presentation of tumor antigens to the adaptive immune system. However, the generation of an adaptive immune response involves highly proliferative processes, which may be adversely affected by DOX-induced cytotoxicity. Therefore, understanding the impact of DOX on dividing T cells becomes crucial, to deepen our understanding and potentially devise strategies to shield anti-tumor immunity from DOX-induced toxicity. Our investigation focused on studying DOX uptake and its effects on human lymphocytes. We collected lymphocytes from healthy donors and BC patients undergoing neoadjuvant chemotherapy (NAC). Notably, patient-derived peripheral blood mononuclear cells (PBMC) promptly internalized DOX when incubated in vitro or isolated immediately after NAC. These DOX-treated PBMCs exhibited significant proliferative impairment compared to untreated cells or those isolated before treatment initiation. Intriguingly, among diverse lymphocyte sub-populations, CD8 + T cells exhibited the highest uptake of DOX. To address this concern, we explored a novel DOX formulation encapsulated in ferritin nanocages (FerOX). FerOX specifically targets tumors and effectively eradicates BC both in vitro and in vivo. Remarkably, only T cells treated with FerOX exhibited reduced DOX internalization, potentially minimizing cytotoxic effects on adaptive immunity.Our findings underscore the importance of optimizing DOX delivery to enhance its antitumor efficacy while minimizing adverse effects, highlighting the pivotal role played by FerOX in mitigating DOX-induced toxicity towards T-cells, thereby positioning it as a promising DOX formulation. This study contributes valuable insights to modern cancer therapy and immunomodulation.
Therapeutic potential of co-signaling receptor modulation in hepatitis B Francesco Andreata, Chiara Laura, Micol Ravà, Caroline C. Krueger, Xenia Ficht, Keigo Kawashima, Cristian G. Beccaria, Federica Moalli, Bianca Partini, Valeria Fumagalli, Giulia Nosetto, Pietro Di Lucia, Ilaria Montali, José M. Garcia-Manteiga, Elisa B. Bono, Leonardo Giustini, Chiara Perucchini, Valentina Venzin, Serena Ranucci, Donato Inverso, Marco De Giovanni, Marco Genua, Renato Ostuni, Enrico Lugli, Masanori Isogawa, Carlo Ferrari, Carolina Boni, Paola Fisicaro, Luca G. Guidotti, Matteo Iannacone Cell, 2024 Reversing CD8 + T cell dysfunction is crucial in treating chronic hepatitis B virus (HBV) infection, yet specific molecular targets remain unclear. Our study analyzed co-signaling receptors during hepatocellular priming and traced the trajectory and fate of dysfunctional HBV-specific CD8 + T cells. Early on, these cells upregulate PD-1, CTLA-4, LAG-3, OX40, 4-1BB, and ICOS. While blocking co-inhibitory receptors had minimal effect, activating 4-1BB and OX40 converted them into antiviral effectors. Prolonged stimulation led to a self-renewing, long-lived, heterogeneous population with a unique transcriptional profile. This includes dysfunctional progenitor/stem-like (T SL ) cells and two distinct dysfunctional tissue-resident memory (T RM ) populations. While 4-1BB expression is ubiquitously maintained, OX40 expression is limited to T SL . In chronic settings, only 4-1BB stimulation conferred antiviral activity. In HBeAg + chronic patients, 4-1BB activation showed the highest potential to rejuvenate dysfunctional CD8 + T cells. Targeting all dysfunctional T cells, rather than only stem-like precursors, holds promise for treating chronic HBV infection.
Priming and Maintenance of Adaptive Immunity in the Liver Keigo Kawashima, Francesco Andreata, Cristian Gabriel Beccaria, Matteo Iannacone Annual Review of Immunology, 2024 The liver's unique characteristics have a profound impact on the priming and maintenance of adaptive immunity. This review delves into the cellular circuits that regulate adaptive immune responses in the liver, with a specific focus on hepatitis B virus infection as an illustrative example. A key aspect highlighted is the liver's specialized role in priming CD8+ T cells, leading to a distinct state of immune hyporesponsiveness. Additionally, the influence of the liver's hemodynamics and anatomical features, particularly during liver fibrosis and cirrhosis, on the differentiation and function of adaptive immune cells is discussed. While the primary emphasis is on CD8+ T cells, recent findings regarding the involvement of B cells and CD4+ T cells in hepatic immunity are also reviewed. Furthermore, we address the challenges ahead and propose integrating cutting-edge techniques, such as spatial biology, and combining mouse models with human sample analyses to gain comprehensive insights into the liver's adaptive immunity. This understanding could pave the way for novel therapeutic strategies targeting infectious diseases, malignancies, and inflammatory liver conditions like metabolic dysfunction-associated steatohepatitis and autoimmune hepatitis.
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus Francesco Andreata, Kelly D. Moynihan, Valeria Fumagalli, Pietro Di Lucia, Danielle C. Pappas, Keigo Kawashima, Irene Ni, Paul H. Bessette, Chiara Perucchini, Elisa Bono, Leonardo Giustini, Henry C. Nguyen, S. Michael Chin, Yik Andy Yeung, Craig S. Gibbs, Ivana Djuretic, Matteo Iannacone Science Translational Medicine, 2024
Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability Valeria Fumagalli, Valentina Venzin, Pietro Di Lucia, Federica Moalli, Xenia Ficht, Gioia Ambrosi, Leonardo Giustini, Francesco Andreata, Marta Grillo, Diletta Magini, Micol Ravà, Christin Friedrich, Jason D. Fontenot, Philippe Bousso, Sarah A. Gilmore, Shahzada Khan, Manuel Baca, Eric Vivier, Georg Gasteiger, Mirela Kuka, Luca G. Guidotti, Matteo Iannacone Science Immunology, 2022
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) Andrea Cossarizza, Hyun‐Dong Chang, Andreas Radbruch, Sergio Abrignani, Richard Addo, Mübeccel Akdis, Immanuel Andrä, Francesco Andreata, Francesco Annunziato, Eduardo Arranz, Petra Bacher, Sudipto Bari, Vincenzo Barnaba, Joana Barros‐Martins, Dirk Baumjohann, Cristian G. Beccaria, David Bernardo, Dominic A. Boardman, Jessica Borger, Chotima Böttcher, Leonie Brockmann, Marie Burns, Dirk H. Busch, Garth Cameron, Ilenia Cammarata, Antonino Cassotta, Yinshui Chang, Fernando Gabriel Chirdo, Eleni Christakou, Luka Čičin‐Šain, Laura Cook, Alexandra J. Corbett, Rebecca Cornelis, Lorenzo Cosmi, Martin S. Davey, Sara De Biasi, Gabriele De Simone, Genny del Zotto, Michael Delacher, Francesca Di Rosa, James Di Santo, Andreas Diefenbach, Jun Dong, Thomas Dörner, Regine J. Dress, Charles‐Antoine Dutertre, Sidonia B. G. Eckle, Pascale Eede, Maximilien Evrard, Christine S. Falk, Markus Feuerer, Simon Fillatreau, Aida Fiz‐Lopez, Marie Follo, Gemma A. Foulds, Julia Fröbel, Nicola Gagliani, Giovanni Galletti, Anastasia Gangaev, Natalio Garbi, José Antonio Garrote, Jens Geginat, Nicholas A. Gherardin, Lara Gibellini, Florent Ginhoux, Dale I. Godfrey, Paola Gruarin, Claudia Haftmann, Leo Hansmann, Christopher M. Harpur, Adrian C. Hayday, Guido Heine, Daniela Carolina Hernández, Martin Herrmann, Oliver Hoelsken, Qing Huang, Samuel Huber, Johanna E. Huber, Jochen Huehn, Michael Hundemer, William Y. K. Hwang, Matteo Iannacone, Sabine M. Ivison, Hans‐Martin Jäck, Peter K. Jani, Baerbel Keller, Nina Kessler, Steven Ketelaars, Laura Knop, Jasmin Knopf, Hui‐Fern Koay, Katja Kobow, Katharina Kriegsmann, H. Kristyanto, Andreas Krueger, Jenny F. Kuehne, Heike Kunze‐Schumacher, Pia Kvistborg, Immanuel Kwok, Daniela Latorre, Daniel Lenz, Megan K. Levings, Andreia C. Lino, Francesco Liotta, Heather M. Long, Enrico Lugli, Katherine N. MacDonald, Laura Maggi, Mala K. Maini, Florian Mair, Calin Manta, Rudolf Armin Manz, Mir‐Farzin Mashreghi, Alessio Mazzoni, James McCluskey, Henrik E. Mei, Fritz Melchers, Susanne Melzer, Dirk Mielenz, Leticia Monin, Lorenzo Moretta, Gabriele Multhoff, Luis Enrique Muñoz, Miguel Muñoz‐Ruiz, Franziska Muscate, Ambra Natalini, Katrin Neumann, Lai Guan Ng, Antonia Niedobitek, Jana Niemz, Larissa Nogueira Almeida, Samuele Notarbartolo, Lennard Ostendorf, Laura J. Pallett, Amit A. Patel, Gulce Itir Percin, Giovanna Peruzzi, Marcello Pinti, A. Graham Pockley, Katharina Pracht, Immo Prinz, Irma Pujol‐Autonell, Nadia Pulvirenti, Linda Quatrini, Kylie M. Quinn, Helena Radbruch, Hefin Rhys, Maria B. Rodrigo, Chiara Romagnani, Carina Saggau, Shimon Sakaguchi, Federica Sallusto, Lieke Sanderink, Inga Sandrock, Christine Schauer, Alexander Scheffold, Hans U. Scherer, Matthias Schiemann, Frank A. Schildberg, Kilian Schober, Janina Schoen, Wolfgang Schuh, Thomas Schüler, Axel R. Schulz, Sebastian Schulz, Julia Schulze, Sonia Simonetti, Jeeshan Singh, Katarzyna M. Sitnik, Regina Stark, Sarah Starossom, Christina Stehle, Franziska Szelinski, Leonard Tan, Attila Tarnok, Julia Tornack, Timothy I. M. Tree, Jasper J. P. van Beek, Willem van de Veen, Klaas van Gisbergen, Chiara Vasco, Nikita A. Verheyden, Anouk von Borstel, Kirsten A. Ward‐Hartstonge, Klaus Warnatz, Claudia Waskow, Annika Wiedemann, Anneke Wilharm, James Wing, Oliver Wirz, Jens Wittner, Jennie H. M. Yang, Juhao Yang European Journal of Immunology, 2021
Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming Giorgia De Simone, Francesco Andreata, Camille Bleriot, Valeria Fumagalli, Chiara Laura, José M. Garcia-Manteiga, Pietro Di Lucia, Stefano Gilotto, Xenia Ficht, Federico F. De Ponti, Elisa B. Bono, Leonardo Giustini, Gioia Ambrosi, Marta Mainetti, Paola Zordan, Alexandre P. Bénéchet, Micol Ravà, Svetoslav Chakarov, Federica Moalli, Marc Bajenoff, Luca G. Guidotti, Florent Ginhoux, Matteo Iannacone Immunity, 2021
A subset of Kupffer cells regulates metabolism through the expression of CD36 Camille Blériot, Emelie Barreby, Garett Dunsmore, Raphaelle Ballaire, Svetoslav Chakarov, Xenia Ficht, Giorgia De Simone, Francesco Andreata, Valeria Fumagalli, Wei Guo, Guochen Wan, Gregoire Gessain, Ahad Khalilnezhad, Xiao Meng Zhang, Nicholas Ang, Ping Chen, Cecilia Morgantini, Valerio Azzimato, Wan Ting Kong, Zhaoyuan Liu, Rhea Pai, Josephine Lum, Foo Shihui, Ivy Low, Connie Xu, Benoit Malleret, Muhammad Faris Mohd Kairi, Akhila Balachander, Olivier Cexus, Anis Larbi, Bernett Lee, Evan W. Newell, Lai Guan Ng, Wint Wint Phoo, Radoslaw M. Sobota, Ankur Sharma, Shanshan W. Howland, Jinmiao Chen, Marc Bajenoff, Laurent Yvan-Charvet, Nicolas Venteclef, Matteo Iannacone, Myriam Aouadi, Florent Ginhoux Immunity, 2021
Nanoparticle-Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment Lucia Salvioni, Stefania Zuppone, Francesco Andreata, Matteo Monieri, Serena Mazzucchelli, Caterina Di Carlo, Lucia Morelli, Chiara Cordiglieri, Lorena Donnici, Raffaele De Francesco, Fabio Corsi, Davide Prosperi, Riccardo Vago, Miriam Colombo Advanced Therapeutics, 2020
Cleaved CD31 as a target for in vivo molecular imaging of inflammation Jonathan Vigne, Sylvie Bay, Rachida Aid-Launais, Guillaume Pariscoat, Guillaume Rucher, Jean Sénémaud, Ariane Truffier, Nadège Anizan, Guillaume Even, Christelle Ganneau, Francesco Andreata, Marie Le Borgne, Antonino Nicoletti, Dominique Le Guludec, Giuseppina Caligiuri, Francois Rouzet Scientific Reports, 2019
Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming Alexandre P. Bénéchet, Giorgia De Simone, Pietro Di Lucia, Francesco Cilenti, Giulia Barbiera, Nina Le Bert, Valeria Fumagalli, Eleonora Lusito, Federica Moalli, Valentina Bianchessi, Francesco Andreata, Paola Zordan, Elisa Bono, Leonardo Giustini, Weldy V. Bonilla, Camille Bleriot, Kamini Kunasegaran, Gloria Gonzalez-Aseguinolaza, Daniel D. Pinschewer, Patrick T. F. Kennedy, Luigi Naldini, Mirela Kuka, Florent Ginhoux, Alessio Cantore, Antonio Bertoletti, Renato Ostuni, Luca G. Guidotti, Matteo Iannacone Nature, 2019
Peptide binding to cleaved CD31 dampens ischemia/reperfusion-induced intestinal injury Quoc Thang Hoang, Alexandre Nuzzo, Liliane Louedec, Sandrine Delbosc, Francesco Andreata, Jamila Khallou-Laschet, Maksud Assadi, Philippe Montravers, Dan Longrois, Olivier Corcos, Giuseppina Caligiuri, Antonino Nicoletti, Jean-Baptiste Michel, Alexy Tran-Dinh Intensive Care Medicine Experimental, 2018
Macrophage CD31 Signaling in Dissecting Aortic Aneurysm Francesco Andreata, Varouna Syvannarath, Marc Clement, Sandrine Delbosc, Kevin Guedj, Giulia Fornasa, Jamila Khallou-Laschet, Marion Morvan, Guillaume Even, Emanuele Procopio, Anh-Thu Gaston, Marie Le Borgne, Lydia Deschamps, Antonino Nicoletti, Giuseppina Caligiuri Journal of the American College of Cardiology, 2018
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou-Khalil, Gilberto Velho, Kamel Mohammedi, Marie-Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catherine Boileau, Michel Marre, Marianne Abifadel, Mathilde Varret, Boris Hansel Diabetes Obesity and Metabolism, 2018
Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection Chien-Chia Chen, Eric Pouliquen, Alexis Broisat, Francesco Andreata, Maud Racapé, Patrick Bruneval, Laurence Kessler, Mitra Ahmadi, Sandrine Bacot, Carole Saison-Delaplace, Marina Marcaud, Jean-Paul Duong Van Huyen, Alexandre Loupy, Jean Villard, Sandrine Demuylder-Mischler, Thierry Berney, Emmanuel Morelon, Meng-Kun Tsai, Marie-Nathalie Kolopp-Sarda, Alice Koenig, Virginie Mathias, Stéphanie Ducreux, Catherine Ghezzi, Valerie Dubois, Antonino Nicoletti, Thierry Defrance, Olivier Thaunat Journal of Clinical Investigation, 2018
